These findings demonstrate that PASMC-derived ET-1 drives the development of PAH in fpnC326Yfl/fl SMMHC-CreERT2+ mice, and that antagonism of the ETA receptor can both prevent and reverse the development of PAH. This evidence concerns the gene MYH11 and pulmonary arterial hypertension.